熱門資訊> 正文

CytoMed Therapeutics报告FY结果

2025-04-29 22:10

CytoMed Therapeutics Limited(GDTC) 0

CytoMed Therapeutics press release (NASDAQ:GDTC): FY topline income amounted to $624,771 in 2024 compared to $588,423 in 2023.
Cash and bank balances amounted to US$3.64 million as of December 31, 2024.
Excluding costs associated with being a public company listed on the NASDAQ Capital Market amounting to $188,341, the company recorded a reduced net loss of $1.66 million for the financial year ended December 31, 2024.

More on CytoMed Therapeutics;

Seeking Alpha’s Quant Rating on CytoMed Therapeutics 
Historical earnings data for CytoMed Therapeutics 
Financial information for CytoMed Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。